A double-blind placebo-controlled study of Org 3770 in depressed outpatients

Journal of Affective Disorders

Volumn 34, Issue 3, 1995, Pages 165-171

  Claghorn, James L ^a   Lesem, Michael D ^a  

^a Claghorn Lesem Research Clinic Inc   (United States)

Author keywords

Major depression; Org 3770

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE; PLACEBO;

ADULT; APPETITE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PERSONALITY INVENTORY; TREATMENT OUTCOME;

EID: 0029070521     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-0327(95)00014-E     Document Type: Article

References (15)

1. Current status of antidepressants: clinical pharmacology and therapy
2. The alpha2-antagonist Org 3770 enhances serotonin transmission in vivo
3. The effect of adrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vitro voltametry
4. Serotonergic mechanisms and the new antidepressants
5. A rating scale for depression
6. A new depression scale designed to be sensitive to change
7. Remeron (Org 3770), an ‘atypical’ antidepressant with ‘typical’ efficacy
8. The pharmacological treatment of depression
9. Monoamines and abnormal behavior: a multiaminergic perspective
10. Biological basis of depression and therapeutic relevance
11. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro
12. A self rating depression scale